0000000000735432

AUTHOR

Iago Rodríguez-lago

0000-0003-1133-4578

showing 2 related works from this author

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score An…

2020

INTRODUCTION: Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR. METHODS: Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a R…

Maleintestinal resectionrecurrent diseaseretrospective studyAnti-Inflammatory AgentsLogistic regressionGastroenterologyimmunology0302 clinical medicineCrohn DiseasepreventioncolonoscopyRecurrenceInterquartile rangeadalimumabIntestinal MucosariskCrohn's diseaseazathioprineMercaptopurinedrug effectGastroenterologyclinical trialColonoscopyTNF protein humanfemaleTreatment Outcomemesalazine030220 oncology & carcinogenesisintestine mucosaFemaleDrug Therapy Combination030211 gastroenterology & hepatologydouble-blindantiinflammatory agentImmunosuppressive Agentsmanagementmedicine.drugcombination drug therapyAdultmedicine.medical_specialtyAdolescentdiagnostic imagingtumor necrosis factormercaptopurineArticleYoung Adult03 medical and health sciencesInternal medicinemedicineAdalimumabHumanshumanproceduresPropensity ScoreRetrospective StudiestherapyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabassociationnatural-historyOdds ratioimmunosuppressive agentmedicine.diseaseInfliximabInfliximabConfidence intervalmulticenter studyConcomitantpathologybusiness
researchProduct

Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicen…

2019

Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] and cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies. Methods PSC-IBD patients were identified from the Spanish ENEIDA registry of GETECCU. Additional data were collected using the AEG-REDCap electronic data capture tool. Results In total, 277 PSC-IBD patients were included, with an incidence rate of 61 PSC cases per 100 000 IBD patient-years, 69.7% …

AdultMalemedicine.medical_specialtyendocrine system diseasesColorectal cancerCholangitis SclerosingRisk AssessmentGastroenterologyInflammatory bowel diseasedigestive systemPrimary sclerosing cholangitisCholangiocarcinomaBile Ducts ExtrahepaticRisk FactorsInterquartile rangeinflammatory bowel diseaseInternal medicineHumansMedicineRetrospective Studiesbusiness.industryPrimary sclerosing cholangitisHazard ratiodigestive oral and skin physiologyGastroenterologyRetrospective cohort studyGeneral MedicineOdds ratioMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurvival AnalysisUlcerative colitisdigestive system diseasesPatient Care ManagementBile Ducts IntrahepaticSpainFemalePrimary sclerosing cholangitis inflammatory bowel disease malignancyColorectal Neoplasmsbusinessmalignancy
researchProduct